argenx NASDAQ: ARGX reported positive top-line results from its Phase III ALKIVIA trial of VYVGART H

Study met primary endpoint of mean Total Improvement Score (TIS) at Week 52 in the combined study po

I am maintaining my "Strong Buy" rating on Immunome (IMNM). This decision is driven by FDA acceptanc

Truist Securities analyst Supawat Thongthip maintains Immunome (NASDAQ:IMNM) with a Buy and raise

Wedbush analyst David Nierengarten maintains Immunome (NASDAQ:IMNM) with a Outperform and raises

Immunome (NASDAQ:IMNM) reported quarterly losses of $(0.65) per share which missed the analyst conse

BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on d

BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (the “Company”) (Nasdaq: IMNM), a biotechnology comp

U.S. stock futures mixed, Dow up 100 points. SpaceX stock falls 10.3% after reporting strong Q2 reve

Atika Capital Management LLC lessened its holdings in Immunome, Inc. (NASDAQ: IMNM) by 21.4% in the

Wedbush analyst David Nierengarten reiterates Immunome (NASDAQ:IMNM) with a Outperform and mainta

BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company committed to

An Immunome insider sold 100,000 shares for $2.4 million based on weighted average prices on July 6,

IMNM jumps 32% in a month. This comes as the FDA accepts varegacestat's NDA for desmoid tumors, with

FDA accepts Immunome's varegacestat NDA for desmoid tumors, with an April 28, 2027, PDUFA date b

Immunome, Inc. (NASDAQ:IMNM), a biotechnology company committed to developing first-in-class and bes

BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company committed to

BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (the “Company”) (Nasdaq: IMNM), a biotechnology comp

Wedbush analyst David Nierengarten reiterates Immunome (NASDAQ:IMNM) with a Outperform and mainta

[url="]Immunome, Inc.[/url] (Nasdaq: IMNM), a biotechnology company committed to developing first-in

Immunome, Inc. (NASDAQ:IMNM), a biotechnology company committed to developing first-in-class and bes

BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company committed to

Immunome, Inc. (IMNM) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transc

Immunome is evolving into a multi-asset targeted oncology platform, anchored by varegacestat's stron

New drug approvals and encouraging pipeline progress should maintain momentum in the Zacks Biomedica

BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (the “Company”) (Nasdaq: IMNM), a biotechnology comp

[url="]Immunome, Inc.[/url] (Nasdaq: IMNM), a biotechnology company committed to developing first-in

BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company committed to

Truist Securities analyst Supawat Thongthip maintains Immunome (NASDAQ:IMNM) with a Buy and raise

Barclays analyst Lukas Shumway initiates coverage on Immunome (NASDAQ:IMNM) with a Overweight rat

[url="]Immunome[/url], Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-c

HC Wainwright & Co. analyst Andres Y. Maldonado reiterates Immunome (NASDAQ:IMNM) with a Buy

Immunome (NASDAQ:IMNM) reported quarterly losses of $(0.48) per share which beat the analyst consens

Immunome, Inc. ("Immunome") (NASDAQ:IMNM), a biotechnology company dedicated to developing f

Craig-Hallum analyst Adam Vogel maintains Immunome (NASDAQ:IMNM) with a Buy and raises the price

Stephens & Co. analyst Sudan Loganathan maintains Immunome (NASDAQ:IMNM) with a Overweight an

Immunome (NASDAQ:IMNM) reported quarterly losses of $(0.75) per share which missed the analyst conse

HC Wainwright & Co. analyst Andres Y. Maldonado initiates coverage on Immunome (NASDAQ:IMNM)

Wedbush analyst David Nierengarten reiterates Immunome (NASDAQ:IMNM) with a Outperform and mainta